Coronavirus Update: New Funding For Valneva, Scotland Looks At Long COVID
Plus, Positive Japan Results For Moderna Vaccine
Executive Summary
France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody.
You may also be interested in...
Coronavirus Update: CoVIg-19 Alliance Ends As Trial Misses Endpoints
Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment.
Coronavirus Update: Takeda Contractor To Manufacture J&J Vaccine; Moderna Starts Pediatric Trial
Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.
Valneva Spies Chance To Join Third Wave Of COVID-19 Vaccines
The company is hoping for strong efficacy from its inactivated vaccine, boosted by two adjuvants